The patent registration for the botulinum toxin alternative, iN-SIS5
▶ Secured the right of novel substance for the cosmetic applications
▶ The patent application for the medical field is under examination
▶ National Stage Application of PCT in the United States, China, Japan, and Europe
We are happy to announce that New Drug Part has secured the patent right for the novel compound being developed as a botulinum toxin alternative, iN-SIS5.
After the examination of Korean Intellectual Property Office (KIPO), the decision for the patent registration as a new substance was granted.
The patent covers not only the proprietary rights to the iN-SIS5 substance itself but also the rights for its cosmetic applications. Specifically, it pertains to the utilization in the cosmetic use by blocking neural transmission through the inhibition of acetylcholine secretion, providing cosmetic effects such as wrinkle improvement, pore reduction and enhanced skin elasticity.
In addition to the cosmetic patent, we have also filed a patent application for iN-SIS5 in the medical field. Moreover, in order to secure patent rights for iN-SIS5 internationally, we are utilizing priority rights from the publicly disclosed PCT application and proceeding with national stage applications in the United States, China, Japan and Europe.
iN-SIS5 has already been registered as a cosmetic ingredient with the International Nomenclature of Cosmetic Ingredients (INCI) and the Korean Ministry of Food and Drug Safety (MFDS) in 2023.
We are strategically establishing plans to expedite commercialization through collaborative partnerships with specialized companies in the production, business and marketing sectors for technologies and promising materials derived from the development process of our novel drugs, such as iN-SIS5. With respect to iN-SIS5, we are engaged with a cosmetic company Nordmason for the joint business and collaborating with a company Dermaject for the development of the iN-SIS5 microneedle products.
Thank you.
it is iNtRON.